Prognostic Significance of Pretreatment 18F-FDG PET/CT in Patients with Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma Treated by Radioimmunotherapy Using 131I-Rituximab | Citedby Results | Acta Haematologica | Karger Publishers

Skip to Main Content

Skip Nav Destination

Prognostic Significance of Pretreatment ¹⁸F-FDG PET/CT in Patients with Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma Treated by Radioimmunotherapy Using ¹³¹I-Rituximab

Acta Haematol (2013) 130 (2): 74–82.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

The role of 18F-FDG PET/CT in patients with diffuse large B-cell lymphoma after radioimmunotherapy using 131I-rituximab as consolidation therapy

Joon Ho Choi
Ilhan Lim
Byung Hyun Byun
Byung Il Kim
Chang Woon Choi
Hye Jin Kang
Dong-Yeop Shin
Sang Moo Lim
Domenico Albano

PLOS ONE (2022) 17 (9): e0273839.

Radioimmunotherapy Combined With Low-Intensity Ultrasound and Microbubbles: A Potential Novel Strategy for Treatment of Solid Tumors

Binwei Lin
Huan Du
Jinjia Fan
Dan Huang
Feng Gao
Jie Li
Yu Zhang
Gang Feng
Tangzhi Dai
Xiaobo Du

Frontiers in Oncology (2021) 11

Targeted alpha immunotherapy of CD20-positive B-cell lymphoma model: dosimetry estimate of 225Ac-DOTA-rituximab using 64Cu-DOTA-rituximab

Chul-Hee Lee
Ilhan Lim
Sang-Keun Woo
Wook Kim
Kwang Il Kim
Kyo Chul Lee
Kanghyon Song
Sang Moo Lim

Annals of Nuclear Medicine (2021) 35 (5): 639.

Combination of 131I-trastuzumab and lanatoside C enhanced therapeutic efficacy in HER2 positive tumor model

Nagarajan Vinod
Jae Hyung Kim
Seungbum Choi
Ilhan Lim

Scientific Reports (2021) 11 (1)

Combination Radioimmunotherapy Strategies for Solid Tumors

Javeria Zaheer
Hyeongi Kim
Yong-Jin Lee
Jin Su Kim
Sang Moo Lim

International Journal of Molecular Sciences (2019) 20 (22): 5579.

Early evaluation of tumor response to 90Y-ibritumomab radioimmunotherapy in relapsed/refractory B cell non-Hodgkin lymphoma: what is the optimal timing for FDG-PET/CT?

Kazuhiro Kitajima
Masaya Okada
Toru Kashiwagi
Kyoko Yoshihara
Tazuko Tokugawa
Akihiro Sawada
Satoshi Yoshihara
Yoshihiro Fujimori
Koichiro Yamakado

European Radiology (2019) 29 (7): 3935.

Predictive value of pre-treatment FDG PET in patients with non-Hodgkin lymphoma treated with radioimmunotherapy: a systematic review

Silvia Morbelli
Selene Capitanio
Luca Guerra
Luigi Rigacci

Clinical and Translational Imaging (2019) 7 (3): 159.

Drug Discovery by Molecular Imaging and Monitoring Therapy Response in Lymphoma

Senthilkumar Kalimuthu
Ju Hye Jeong
Ji Min Oh
Byeong-Cheol Ahn

International Journal of Molecular Sciences (2017) 18 (8): 1639.

DVH- and NTCP-based dosimetric comparison of different longitudinal margins for VMAT-IMRT of esophageal cancer

S Münch
M Oechsner
SE Combs
D Habermehl

Radiation Oncology (2017) 12 (1)

Radioimmunotherapy in non-Hodgkin lymphoma: Prediction and assessment of response

Mahsa Eskian
MirHojjat Khorasanizadeh
Francoise Kraeber-Bodere
Nima Rezaei

Critical Reviews in Oncology/Hematology (2016) 107: 182.

Maximum standardized uptake value on positron emission tomography/computed tomography predicts clinical outcome in patients with relapsed or refractory diffuse large B-cell lymphoma

Hee Ryeong Jang
Moo Kon Song
Joo Seop Chung
Deok Hwan Yang
Jeong Ok Lee
Junshik Hong
Su Hee Cho
Seong Jang Kim
Dong Hoon Shin
Young Joo Park
Jin-Suk Kang
Jeong Eun Lee
Moon Won Lee
Ho-Jin Shin

Blood Research (2015) 50 (2): 97.

Trial Watch: Radioimmunotherapy for oncological indications

Norma Bloy
Jonathan Pol
Gwenola Manic
Ilio Vitale
Alexander Eggermont
Jérôme Galon
Eric Tartour
Laurence Zitvogel
Guido Kroemer
Lorenzo Galluzzi

OncoImmunology (2014) 3 (9): e954929.